FDA Clearance Tracker · P990018-S006
ACUVUE® Abiliti Overnight and ACUVUE® Abiliti Overnight Therapeutic Lenses for Myopia Management
Last checked: Nov 20, 2026Latest source record: May 6, 2021 (this decision)Source: openFDAMethods & limitations
Decided
May 6, 2021
Approved
Time to decision
105 days
Received Jan 21, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P990018-S006
- Device name
- ACUVUE® Abiliti Overnight and ACUVUE® Abiliti Overnight Therapeutic Lenses for Myopia Management
- Applicant
- Menicon Co, Ltd.
- Applicant location
- Nagoya
- Received
- Jan 21, 2021
- Decided
- May 6, 2021
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P990018
Device type
- Device class
- Class III
- Regulation
- 21 CFR 886.5916
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for addition of the following private label trade names for the Menicon Z Night (tisilfocon A) Contact Lenses for Overnight Wear: ACUVUE® Abiliti Overnight and ACUVUE® Abiliti Overnight Therapeutic Lenses for Myopia Management.
Source documents
Other decisions for Menicon Co, Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262495 · Decided Sep 17, 2026 · 59 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.